Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia
It is the medical evaluation and long-term management of obesity, overweight, insulin resistance, and weight-related health risk
So, these are some things we really need to study now
Further studies are needed here, but it has the potential as a treatment for obesity and diabetes.[ref] EGCG: Found in green tea, EGCG has been shown in cell studies to increase GLP-1 secretion.[ref] Yerba mate tea: Animal studies show that Yerba mate induces GLP-1 secretion.[ref] Increase bitterness: The TAS2R38 gene, a bitter taste receptor, is active in the same cells in the gastrointestinal tract as glucagon-like peptide 1 cells
Follow-ups with blood work are rare unless you report new symptoms or side effects
Indikationen [Bearbeiten | Quelltext bearbeiten] Diabetes mellitus Typ 2 [Bearbeiten | Quelltext bearbeiten] Der primre Einsatzbereich der Inkretinmimetika ist die Therapie des Diabetes mellitus Typ 2